Showing 2,301 - 2,320 results of 32,676 for search '(( significant decrease decrease ) OR ( significantly ((reduced decrease) OR (reduced disease)) ))', query time: 0.65s Refine Results
  1. 2301
  2. 2302
  3. 2303
  4. 2304
  5. 2305

    Riboflavin inhibits growth and reduces virulence of <i>Cryptococcus neoformans in vitro</i> by membrane disruption and excessive accumulation of reactive oxygen species and exhibit... by Jian Huang (7250)

    Published 2025
    “…Finally, in mouse models of intranasal and intravenous infection, RF treatment significantly reduced the fungal burden in multiple organs, reduced lung and brain damage, and decreased the levels of plasma interferon (IFN)-γ, tumor necrosis factor (TNF)-α, and interleukin (IL)-4 in the early stage of infection. …”
  6. 2306

    Vertebral cancellous tissueμCT parameters are not significantly affected by aging from 16 to 21 weeks, housing type, or microgravity. by Rukmani Cahill (20939813)

    Published 2025
    “…Nonsignificant trends implicate an effect of spaceflight reducing BV/TV, increasing DA, and reducing Tb.N. Data shown are the mean ±  standard deviation with a scatter plot (ns: non-significant). …”
  7. 2307

    Discovery of an Orally Active PDE1 Inhibitor for Disease-Modifying Treatment of Postmenopausal Osteoporosis via Dual Anabolic-Antiresorptive Mechanisms by Farman M. Abbasi (22318766)

    Published 2025
    “…In ovariectomized mice, <b>5cc</b> administration (5 mg/kg) improved the trabecular microarchitecture, bone mineral density, and strength, at levels comparable to teriparatide, while significantly reducing bone resorption markers. With 13.57% oral bioavailability and selectivity for PDE1A1 (32% inhibition at 500 nM), <b>5cc</b> offers an innovative therapeutic candidate for PMO with a dual anabolic-antiresorptive profile and oral efficacy, warranting further clinical development.…”
  8. 2308

    Discovery of an Orally Active PDE1 Inhibitor for Disease-Modifying Treatment of Postmenopausal Osteoporosis via Dual Anabolic-Antiresorptive Mechanisms by Farman M. Abbasi (22318766)

    Published 2025
    “…In ovariectomized mice, <b>5cc</b> administration (5 mg/kg) improved the trabecular microarchitecture, bone mineral density, and strength, at levels comparable to teriparatide, while significantly reducing bone resorption markers. With 13.57% oral bioavailability and selectivity for PDE1A1 (32% inhibition at 500 nM), <b>5cc</b> offers an innovative therapeutic candidate for PMO with a dual anabolic-antiresorptive profile and oral efficacy, warranting further clinical development.…”
  9. 2309

    Discovery of an Orally Active PDE1 Inhibitor for Disease-Modifying Treatment of Postmenopausal Osteoporosis via Dual Anabolic-Antiresorptive Mechanisms by Farman M. Abbasi (22318766)

    Published 2025
    “…In ovariectomized mice, <b>5cc</b> administration (5 mg/kg) improved the trabecular microarchitecture, bone mineral density, and strength, at levels comparable to teriparatide, while significantly reducing bone resorption markers. With 13.57% oral bioavailability and selectivity for PDE1A1 (32% inhibition at 500 nM), <b>5cc</b> offers an innovative therapeutic candidate for PMO with a dual anabolic-antiresorptive profile and oral efficacy, warranting further clinical development.…”
  10. 2310

    Analyze data. by Xinhui Zhang (1624039)

    Published 2025
    Subjects:
  11. 2311
  12. 2312
  13. 2313
  14. 2314
  15. 2315
  16. 2316
  17. 2317
  18. 2318
  19. 2319
  20. 2320